Arrhythmogenic effects of acute free fatty acid mobilization on ischemic heart. 1976

N Yamazaki, and Y Suzuki, and T Kamikawa, and K Ogawa, and K Mizutani, and N Kakizawa, and M Yamamoto

The mechanism of action of the acute abnormal rise of plasma free fatty acids (FFA) in the provocation of arrhythmia in ischemic heart was studied by means of electron spin resonance (ESR) spectrometer. A sudden and abnormal rise of plasma FFA caused a significant fall of the respiratory control index (RCI) of the amount of free radical myocardial mitochondria in state 4 respiration. Based on these findings, a sudden and abnormal rise of plasma FFA seems to further facilitate the uncoupling of oxidative phosphorylation in the myocardial mitochondria of the ischemic portion of the heart. These observations indicate that it may play an important role in the provocation of arrhythmia by high plasma FFA on the ischemic heart. Nicomol (2,2,6,6,-tetrakis (nicotinoyloxymethyl) cyclohexanol), an inhibitor for the rapid rise of plasma FFA, was effective in the treatment and prevention of arrhythmia in ischemic heart disease and diabetes mellitus.

UI MeSH Term Description Entries
D008053 Lipid Mobilization LIPOLYSIS of stored LIPIDS in the ADIPOSE TISSUE to release FREE FATTY ACIDS. Mobilization of stored lipids is under the regulation of lipolytic signals (CATECHOLAMINES) or anti-lipolytic signals (INSULIN) via their actions on the hormone-sensitive LIPASE. This concept does not include lipid transport. Lipid Mobilizations,Mobilization, Lipid,Mobilizations, Lipid
D008929 Mitochondria, Heart The mitochondria of the myocardium. Heart Mitochondria,Myocardial Mitochondria,Mitochondrion, Heart,Heart Mitochondrion,Mitochondria, Myocardial
D009539 Nicotinic Acids 2-, 3-, or 4-Pyridinecarboxylic acids. Pyridine derivatives substituted with a carboxy group at the 2-, 3-, or 4-position. The 3-carboxy derivative (NIACIN) is active as a vitamin. Acids, Nicotinic
D009638 Norepinephrine Precursor of epinephrine that is secreted by the ADRENAL MEDULLA and is a widespread central and autonomic neurotransmitter. Norepinephrine is the principal transmitter of most postganglionic sympathetic fibers, and of the diffuse projection system in the brain that arises from the LOCUS CERULEUS. It is also found in plants and is used pharmacologically as a sympathomimetic. Levarterenol,Levonorepinephrine,Noradrenaline,Arterenol,Levonor,Levophed,Levophed Bitartrate,Noradrenaline Bitartrate,Noradrénaline tartrate renaudin,Norepinephrin d-Tartrate (1:1),Norepinephrine Bitartrate,Norepinephrine Hydrochloride,Norepinephrine Hydrochloride, (+)-Isomer,Norepinephrine Hydrochloride, (+,-)-Isomer,Norepinephrine d-Tartrate (1:1),Norepinephrine l-Tartrate (1:1),Norepinephrine l-Tartrate (1:1), (+,-)-Isomer,Norepinephrine l-Tartrate (1:1), Monohydrate,Norepinephrine l-Tartrate (1:1), Monohydrate, (+)-Isomer,Norepinephrine l-Tartrate (1:2),Norepinephrine l-Tartrate, (+)-Isomer,Norepinephrine, (+)-Isomer,Norepinephrine, (+,-)-Isomer
D010101 Oxygen Consumption The rate at which oxygen is used by a tissue; microliters of oxygen STPD used per milligram of tissue per hour; the rate at which oxygen enters the blood from alveolar gas, equal in the steady state to the consumption of oxygen by tissue metabolism throughout the body. (Stedman, 25th ed, p346) Consumption, Oxygen,Consumptions, Oxygen,Oxygen Consumptions
D003327 Coronary Disease An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels. Coronary Heart Disease,Coronary Diseases,Coronary Heart Diseases,Disease, Coronary,Disease, Coronary Heart,Diseases, Coronary,Diseases, Coronary Heart,Heart Disease, Coronary,Heart Diseases, Coronary
D004285 Dogs The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065) Canis familiaris,Dog
D004578 Electron Spin Resonance Spectroscopy A technique applicable to the wide variety of substances which exhibit paramagnetism because of the magnetic moments of unpaired electrons. The spectra are useful for detection and identification, for determination of electron structure, for study of interactions between molecules, and for measurement of nuclear spins and moments. (From McGraw-Hill Encyclopedia of Science and Technology, 7th edition) Electron nuclear double resonance (ENDOR) spectroscopy is a variant of the technique which can give enhanced resolution. Electron spin resonance analysis can now be used in vivo, including imaging applications such as MAGNETIC RESONANCE IMAGING. ENDOR,Electron Nuclear Double Resonance,Electron Paramagnetic Resonance,Paramagnetic Resonance,Electron Spin Resonance,Paramagnetic Resonance, Electron,Resonance, Electron Paramagnetic,Resonance, Electron Spin,Resonance, Paramagnetic
D005230 Fatty Acids, Nonesterified FATTY ACIDS found in the plasma that are complexed with SERUM ALBUMIN for transport. These fatty acids are not in glycerol ester form. Fatty Acids, Free,Free Fatty Acid,Free Fatty Acids,NEFA,Acid, Free Fatty,Acids, Free Fatty,Acids, Nonesterified Fatty,Fatty Acid, Free,Nonesterified Fatty Acids
D005609 Free Radicals Highly reactive molecules with an unsatisfied electron valence pair. Free radicals are produced in both normal and pathological processes. Free radicals include reactive oxygen and nitrogen species (RONS). They are proven or suspected agents of tissue damage in a wide variety of circumstances including radiation, damage from environment chemicals, and aging. Natural and pharmacological prevention of free radical damage is being actively investigated. Free Radical

Related Publications

N Yamazaki, and Y Suzuki, and T Kamikawa, and K Ogawa, and K Mizutani, and N Kakizawa, and M Yamamoto
January 1972, Recent advances in studies on cardiac structure and metabolism,
N Yamazaki, and Y Suzuki, and T Kamikawa, and K Ogawa, and K Mizutani, and N Kakizawa, and M Yamamoto
March 1964, Life sciences (1962),
N Yamazaki, and Y Suzuki, and T Kamikawa, and K Ogawa, and K Mizutani, and N Kakizawa, and M Yamamoto
March 1966, Pharmacological reviews,
N Yamazaki, and Y Suzuki, and T Kamikawa, and K Ogawa, and K Mizutani, and N Kakizawa, and M Yamamoto
September 1963, Metabolism: clinical and experimental,
N Yamazaki, and Y Suzuki, and T Kamikawa, and K Ogawa, and K Mizutani, and N Kakizawa, and M Yamamoto
October 1968, Canadian journal of biochemistry,
N Yamazaki, and Y Suzuki, and T Kamikawa, and K Ogawa, and K Mizutani, and N Kakizawa, and M Yamamoto
February 1978, The Journal of clinical endocrinology and metabolism,
N Yamazaki, and Y Suzuki, and T Kamikawa, and K Ogawa, and K Mizutani, and N Kakizawa, and M Yamamoto
July 1988, [Hokkaido igaku zasshi] The Hokkaido journal of medical science,
N Yamazaki, and Y Suzuki, and T Kamikawa, and K Ogawa, and K Mizutani, and N Kakizawa, and M Yamamoto
June 1986, Acta physiologica Scandinavica,
N Yamazaki, and Y Suzuki, and T Kamikawa, and K Ogawa, and K Mizutani, and N Kakizawa, and M Yamamoto
June 1965, Life sciences,
N Yamazaki, and Y Suzuki, and T Kamikawa, and K Ogawa, and K Mizutani, and N Kakizawa, and M Yamamoto
January 1965, Psychosomatic medicine,
Copied contents to your clipboard!